A Probable Case of Kava Induced Cholestatic Liver Injury with Causality Assessment by the updated RUCAM

Authors

  • Harry Zobel Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA and Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania, USA
  • Madhuri Chengappa Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania, USA
  • Ipsit Pandya Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania, USA
  • Izat Hjazi Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania, USA

DOI:

https://doi.org/10.12970/2308-8044.2020.08.11

Keywords:

 Herb induced liver injury, kava, RUCAM, causality assessment, dietary supplements.

Abstract

 Kava's safety profile continues to be debated as previous case reports have not performed adequate causality assessments or have only demonstrated possible causality. Furthermore, the pathogenicity of kava induced liver injury remains poorly understood. We describe here a case of cholestatic liver injury in a 48-year-old male with a two-month history of kava ingestion who presented with jaundice. After adjusting medications and stopping kava, the patient’s liver enzymes trended down. Using the Roussel Uclaf Causality Assessment Method (RUCAM), which is the most up-to-date diagnostic causality algorithm for herb and drug induced liver injury, kava was determined to be the probable cause of the patient’s liver injury along with possible causality from comedication. As comedication is a common feature among kava-induced liver injury, the pathogenicity may involve metabolic interactions between kavalactones and other exogenous substrates. Based on these findings, providers should continue warning patients of potentially fatal liver injury associated with kava use, especially with comedication, until quality control standards can ensure its safety. 

References

Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products -United States, Germany, and Switzerland, 1999-2002. Morb Mortal Wkly Rep 2002; 51(47): 1065-7.

U.S. Food and Drug Administration. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury [Internet]. Safety Alerts & Advisories. Center for Food Safety and Applied Nutrition; 2002 [cited 2020 Mar 11]. Available from: http://wayback.archive-it.org/7993/20171114232640/https://www.fda.gov/Food/RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ucm085482.htm

National Center for Complementary and Integrative Health. Kava Linked to Liver Damage [Internet]. NIH 2010 [cited 2020 Feb 13]. Available from: https://www.nccih.nih.gov/health/kava#: ~: text=The use of kava has,to drive or operate machinery.

Gardiner P, Graham R, Legedza ATR, Ahn AC, Eisenberg DM, Phillips RS. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 2007; 13(2): 22-9.

National Toxicology Program. Nomination Summary for Kava kava extract (N99012) [Internet]. 1999 [cited 2020 Mar 30]. Available from: https://ntp.niehs.nih.gov/getinvolved/ nominate/summary/nm-n99012.html

Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003; (1). https://doi.org/10.1002/14651858.CD003383

Escher M. Drug points: Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ [Internet] 2001 Jan 20; 322(7279): 139-139. https://doi.org/10.1136/bmj.322.7279.139

Becker MW, Lourençone EMS, De Mello AF, Branco A, Filho EMR, Blatt CR, et al. Liver transplantation and the use of KAVA: Case report. Phytomedicine 2019; 56(January 2018): 21-6. https://doi.org/10.1016/j.phymed.2018.08.011

Russmann S, Lauterburg B, Helbling A. Kava Hepatotoxicity. Ann Intern Med 2001; 135(1): 68. https://doi.org/10.7326/0003-4819-135-1-200107030-00036

Campo J V., McNabb J, Perel JM, Mazariegos G V., Hasegawa SL, Reyes J. Kava-induced fulminant hepatic failure. J Am Acad Child Adolesc Psychiatry [Internet] 2002; 41(6): 631-2. https://doi.org/10.1097/00004583-200206000-00001

Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol - Clin Toxicol 2003; 41(2): 109-13. https://doi.org/10.1081/CLT-120019123

Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. DMW - Dtsch Medizinische Wochenschrift [Internet] 2008 Mar 25; 123(47): 1410-4. https://doi.org/10.1055/s-2007-1024196

Teschke R. Kava hepatotoxicity: Pathogenetic aspects and prospective considerations. Liver Int 2010; 30(9): 1270-9. https://doi.org/10.1111/j.1478-3231.2010.02308.x

Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2016; 17(1): 14. https://doi.org/10.3390/ijms17010014

Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol [Internet] 2014 Aug; 61(2): 293-300. https://doi.org/10.1016/j.jhep.2014.03.026

Teschke R. Kava hepatotoxicity. A clinical review. Ann Hepatol [Internet] 2010; 9(3): 251-65. https://doi.org/10.1016/S1665-2681(19)31634-5

White CM. The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava. J Clin Pharmacol 2018; 58(11): 1396-405. https://doi.org/10.1002/jcph.1263

Teschke R, Schmidt M. Controversy on a Newly Published Case of Assumed Acute Liver Failure One Day after Kava Use: Issues of Confounders, Causality, and an Undetermined Cause. J Mod Med Chem [Internet] 2020 Aug 10; 8(1): 33-40. https://doi.org/10.12970/2308-8044.2020.08.04

Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA - J Am Med Assoc 2010; 304(19): 2174-5. https://doi.org/10.1001/jama.2010.1689

Downloads

Published

2020-04-20

Issue

Vol. 8 (2020)

Section

Articles